However, about half of the patients treated by endocrine therapy will eventually relapse, which makes it a significant clinical problem.7 Thus, further understanding of the underlying mechanisms and insights into new components of ERɑ signalling is critical in dealing with endocrine resistance in patients with breast cancer. Here, ESR1 is linked to breast cancer.